Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EMA

- PMLiVE

BMS cuts Orencia price to win NICE over

Draft guidance now backs drug for earlier stage of rheumatoid arthritis treatment

- PMLiVE

Pfizer reports strong data with new breast cancer candidate

Phase II results suggest progression-free survival benefits for PD-0332991

- PMLiVE

Andrew Gengos joins ImmunoCellular as CEO

Will lead company as it initiates phase II trials investigating brain tumour vaccine

- PMLiVE

Pfizer launches personalised lung cancer drug Xalkori in UK

Becomes first treatment on the market for ALK-positive NSCLC

- PMLiVE

Pharma R&D costs up tenfold since 1970s

Average cost to bring a drug to market now $1.9bn, according to the Office for Health Economics

- PMLiVE

FDA approves Exelixis’ Cometriq for rare thyroid cancer

Genomics-based discovery company also submits the drug to EU regulators

- PMLiVE

EMA publishes drug shortages plan

Globalisation of manufacturing among key issues to address

- PMLiVE

Ranbaxy recalls generic Lipitor in US

Several batches withdrawn after some products found to contain small particles of glass

Charles Morris appointed chief development officer at ImmunoGen

Previously worked in oncology for Allos, Cephalon and AstraZeneca

- PMLiVE

Postcards from China, part 3

Improving market access through integrated solutions

- PMLiVE

EC consults on launch timing for new pharmacovigilance symbol

Wants to know how introduction of 'black symbol' will affect pharma

Novartis building

Novartis to issue stark warning to UK at crisis meeting

Says UK needs to address decline in pharma R&D

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links